Welldoc Submits 510(k) to FDA for CGM-Informed Glucose Prediction Feature

COLUMBIA, Md.–(BUSINESS WIRE)–Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Continuous Glucose Monitor (CGM)-Informed Glucose Prediction Feature. This…


Click here to view the original article.